Please login to the form below

Not currently logged in
Email:
Password:

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

J&J

An experimental vaccine candidate currently being developed by Johnson and Johnson has proved promising in early, pre-clinical studies.

The vaccine, Ad26.COV2.S, induced a robust immune response in monkeys, demonstrated by high levels of neutralising antibodies. According to J&J, this immune response successfully prevented subsequent infection and provided complete or near-complete protection from the SARS-CoV-2 virus, which causes COVID-19.

In the studies, J&J’s researchers initially immunised the animals with a number of vaccine candidates – out of seven vaccine prototypes tested in the study, scientists found that Ad26.COV2.S elicited the highest levels of neutralising antibodies to SARS-CoV-2.

All six animals that received a single immunisation with the lead vaccine candidate showed no detectable virus in their lower respiratory tract after exposure to SARS-CoV-2, and only one showed very low levels of the virus in a nasal swab at two time points.

Based on the promising results from the animal study, J&J has started a phase 1/2a human clinical trial of the vaccine trial in the US and Belgium. This clinical trial programme will evaluate both one- and two-dose regimens of Ad26.COV2.S in over 1,000 health adults aged 18 to 55 years, as well as adults aged 65 and over.

If all goes to plan in the first-in-human clinical trials, J&J hopes to begin a pivotal phase 3 trial of the single vaccine dose versus placebo in September, as well as a parallel phase 3 study of a two-dose regimen versus placebo.

The company added that it will emphasise representation of populations that have been the most impacted by the pandemic in the phase 3 trial programme. In the US, this would include significant representation of participants over 65 years of age and certain minority ethnic groups.

J&J and the US government’s Biomedical Advanced Research and Development Authority (BARDA) have collectively committed $1bn to the vaccine project, which will be spent on R&D and clinical testing of the vaccine.

“We are excited to see these pre-clinical data because they show our SARS-CoV-2 vaccine candidate generated a strong antibody response and provided protection with a single dose,” said Paul Stoffels, vice chairman of the executive committee and chief scientific officer, J&J.

“The findings give us confidence as we progress our vaccine development and upscale manufacturing in parallel, having initiated a phase 1/2a trial in July with the intention to move into a phase 3 trial in September," he added.

Article by
Lucy Parsons

31st July 2020

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

7 important considerations for creating an inclusive clinical trial website
You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Employee engagement
Route 66: can remote working put two-thirds of us back on the road to engaged employment?
Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Demonstrating the value of HCP self-serve portals
Develop the art of setting KPIs and metrics aligned to your specific objectives, target personas, key educational messages, content, website features and journeys....

Infographics